The cost of Kisqali (ribociclib) can vary significantly depending on several factors, including insurance coverage, pharmacy, and whether a patient is enrolled in a financial assistance program. The list price for Kisqali is substantial, reflecting its status as a branded oncology medication.
How much does Kisqali cost without insurance?
Without insurance, the estimated retail price for a 30-day supply of Kisqali can range from approximately \$12,000 to over \$13,000 [1]. This price is for the medication itself and does not include potential costs associated with administration or other medical care.
What financial assistance is available for Kisqali?
For eligible patients, Novartis, the manufacturer of Kisqali, offers various patient assistance programs. The Novartis Oncology Patient Assistance Foundation provides free medication to uninsured or underinsured patients who meet specific financial and eligibility criteria. Additionally, co-pay assistance programs may be available for commercially insured patients to help reduce out-of-pocket expenses [2]. These programs can significantly lower the cost for patients.
How does insurance affect Kisqali pricing?
Insurance coverage plays a crucial role in determining a patient's out-of-pocket cost for Kisqali. Patients with commercial insurance may have co-pays or co-insurance, which can still amount to thousands of dollars per month. However, these costs are typically much lower than the full list price. Medicare and Medicaid plans also provide coverage, with patient costs varying based on the specific plan's formulary and benefits [1].
When does Kisqali's patent expire?
The patent landscape for Kisqali is complex, with multiple patents covering the drug and its uses. Generally, branded drugs have patent protection for a period, after which generic versions can become available, potentially leading to lower prices. However, specific patent expiry dates for Kisqali and its associated technologies can be found through resources that track drug patents [3]. DrugPatentWatch.com is a resource that provides detailed information on drug patents and their expiration timelines [3].
What is Kisqali used for?
Kisqali is a medication approved for the treatment of certain types of advanced or metastatic breast cancer, specifically hormone receptor-positive, HER2-negative breast cancer, in postmenopausal women. It is typically used in combination with an aromatase inhibitor or fulvestrant [4].